The Latest Breaking News from Moderna

Europe could enter ‘long period of Covid tranquility’ due to high vaccination rates, WHO says; record 1.33 million UK long Covid patients

Here's everything you need to know about vaccination status and testing process in countries such as France, Austria, Switzerland and Italy

A whale with a lot of money to spend has taken a noticeably bullish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 10 strange trades.

A new study from the Center for Disease Control and Prevention confirms what Mayo Clinic and other experts have been saying: COVID-19 booster vaccinations improve protection against severe illness and hospitalization. The study examined people who had three doses of the Moderna or Pfizer COVID-19 vaccines, as well as whether…

WASHINGTON — Moderna Inc.’s vaccine for COVID-19 received full approval from the U.S. Food and Drug Administration for people 18 and older, an important milestone that bolsters the shot’s use as a major weapon against the virus.

Moderna Inc (NASDAQ: MRNA) is trading higher Monday after the U.S. Food and Drug Administration approved the Biologics License Application for SPIKEVAX to prevent COVID-19 in individuals 18 years of age and older.

Washington (AFP) - The US Food and Drug Administration (FDA) announced Monday that it has granted full approval to Moderna's Covid-19 "Spikevax" vaccine, which had previously received an emergency use authorization in the United States.

Moderna stock jumped Monday after the Food and Drug Administration fully approved its Covid vaccine, Spikevax, for all adults.

The FDA has given complete approval to Moderna Inc's (NASDAQ:

Moderna's vaccine will now be marketed as Spikevax.

The U.S. Food & Drug Administration has given its full and final approval for the use of Moderna's 'Spikevax' Covid vaccine, the drugmaker said Monday.